Niagen Bioscience

Wellness Adoption And Academic Trials Will Define Future Opportunity

AnalystConsensusTarget

Not Invested

Consensus Narrative from 5 Analysts

Published

25 Aug 25

Updated

25 Aug 25

AnalystConsensusTarget's Fair Value

US$16.04

37.4% undervalued

25 Aug

US$10.04

187.7%

4.3%

187.7%

4.3%

Author's Valuation

US$16.0

37.4% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates0

AnalystConsensusTarget Fair Value

US$16.0

37.4% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

17.88%

Life Sciences revenue growth rate

0.32%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

7.14%

Calculation

US$32.97m

Earnings '28

53.85x

PE Ratio '28

US$1.78b

Market Cap '28

US$1.78b

Market Cap '28

90.95m

No. shares '28

US$19.52

Share Price '28

US$19.52 Share Price '28

Discounted to 2025 @ 7.14% p.a.

US$15.87

Fair Value '25